You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PI3K/mTOR

Showing 1 - 25 of 9,196
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer Trial in Boston (Palbociclib, Gedatolisib)

Recruiting
  • Lung Cancer Squamous Cell
  • +3 more
  • Boston, Massachusetts
  • +2 more
Jan 9, 2023

PIK3CA Mutation-Related Tumors Trial in Shanghai (WX390)

Completed
  • PIK3CA Mutation-Related Tumors
  • Shanghai, Shanghai, China
    Shanghai East Hospital
Nov 9, 2023

Bile Acids in Acute Insulin Resistance

Recruiting
  • PI3K Gene Mutation
  • +4 more
  • Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
  • New York, New York
    Columbia University Medical Center
Oct 6, 2022

Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +

Not yet recruiting
  • Breast Cancer
  • +3 more
  • Miami, Florida
    University of Miami
Apr 12, 2023

HNSCC Trial in Houston (Bimiralisib)

Terminated
Has Results
  • HNSCC
  • Houston, Texas
    M.D. Anderson Cancer Center
Dec 22, 2021

Everolimus-containing Chemotherapy in HER2- mBC PI3K/AKT/mTOR

Completed
  • Breast Cancer
  • +2 more
  • No intervention, it was a retrospective study.
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Sep 13, 2021

Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of

Not yet recruiting
  • Triple Negative Breast Cancer
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 25, 2023

High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma Trial in Worldwide (Ribociclib, Everolimus)

Not yet recruiting
  • High Grade Glioma
  • +8 more
  • Aurora, Colorado
  • +17 more
May 2, 2023

Low Grade Glioma, World Health Organization (WHO) Grade II Astrocytomas, Oligodendrogliomas Trial in San Francisco (Everolimus,

Terminated
  • Low Grade Glioma
  • +3 more
  • San Francisco, California
    University of California, San Francisco
Nov 3, 2021

Glioblastoma, Adult Trial in United States (Paxalisib (GDC-0084))

Active, not recruiting
  • Glioblastoma, Adult
  • Paxalisib (GDC-0084)
  • Los Angeles, California
  • +5 more
Aug 16, 2022

Breast Cancer Trial in Los Angeles, Bronx (Gedatolisib, Faslodex, Palbociclib)

Active, not recruiting
  • Breast Cancer
  • Los Angeles, California
  • +1 more
Jan 25, 2022

Breast Cancer Trial in Beijing (Inetetamab, Rapamycin, Pyrotinib)

Not yet recruiting
  • Breast Cancer
  • Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Jan 31, 2021

Tumor Trial in Worldwide (PF-05212384 (gedatolisib), Docetaxel, Cisplatin)

Completed
Has Results
  • Neoplasm
  • PF-05212384 (gedatolisib)
  • +3 more
  • Birmingham, Alabama
  • +28 more
Sep 9, 2021

Endometrial Cancer, Ovarian Cancer Trial in Houston (Copanlisib, fulvestrant)

Recruiting
  • Endometrial Cancer
  • Ovarian Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2022

Relapsed/Refractory Large Granular T Lymphocytic Leukemia Trial in Zhoukou, Tianjin (Linperlisib)

Not yet recruiting
  • Relapsed/Refractory Large Granular T Lymphocytic Leukemia
  • Zhoukou, Henan, China
  • +1 more
Dec 22, 2022

Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment Trial in Zhoukou, Tianjin (Linperlisib)

Not yet recruiting
  • Autoimmune Hemolytic Anemia
  • Failure of Two Rounds of Treatment
  • Zhoukou, Henan, China
  • +1 more
Jan 7, 2023

Metastatic Breast Cancer Trial in East Melbourne (BYl719)

Completed
  • Metastatic Breast Cancer
  • East Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Aug 11, 2022

Hyperglycemia Drug Induced Trial in Durham (REMD-477)

Terminated
  • Hyperglycemia Drug Induced
  • REMD-477
  • Durham, North Carolina
    Duke University Medical Center
Nov 4, 2022

Estrogen Receptor-positive Breast Cancer Trial in Nashville (2-Week Ketogenic Diet, Letrozole)

Recruiting
  • Estrogen Receptor-positive Breast Cancer
  • Nashville, Tennessee
    Vanderbilt-Ingram Cancer Center
Sep 20, 2022

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,

Active, not recruiting
  • Estrogen Receptor-positive Breast Cancer
  • +5 more
  • PI3K inhibitor BYL719
  • +3 more
  • Boston, Massachusetts
  • +1 more
Oct 14, 2022

Brain and CNS Tumors Trial in Memphis (GDC-0084, radiation therapy)

Completed
  • Brain and Central Nervous System Tumors
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jan 13, 2023

Leukemia, Acute Lymphocytic Trial in Durham (Copanlisib)

Recruiting
  • Leukemia, Acute Lymphocytic
  • Durham, North Carolina
    Duke Cancer Center
Jun 28, 2022

Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer Trial (OP-1250, Ribociclib, Alpelisib)

Not yet recruiting
  • Metastatic Breast Cancer
  • +3 more
  • (no location specified)
Aug 18, 2022

Melanoma and Other Malignant Tumors of Skin, Metastatic Melanoma Trial in Houston (GSK2636771, Pembrolizumab)

Active, not recruiting
  • Melanoma and Other Malignant Neoplasms of Skin
  • Metastatic Melanoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 22, 2022

Alzheimer Trial in Hialeah, Maitland, Winter Park ([18F]PI-2620)

Recruiting
  • Alzheimer Disease
  • Hialeah, Florida
  • +2 more
Jan 18, 2023